EGFR and lung cancer: We previously showed that targeting estrogen receptor β (ERβ) with the ER blocker fulvestrant (F), together with targeting the family of epidermal growth factor receptors (HERs) with the pan-HER tyrosine kinase inhibitor (TKI) dacomitinib (D), had a synergistic antitumor effect in ERβ+ lung cancer, producing a gene signature that better predicts clinical outcomes [7].